The RSK family of kinases: emerging roles in cellular signalling
By R. Anjum, J. Blenis. Nature reviews. Molecular cell biology, 2008
796 citations recorded by the source corpus.
Subfields: Molecular Biology
View Paper: https://www.semanticscholar.org/paper/238a5a839d1a789cc5a1a538e32a7459a3c01809
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- R. Roskoski
- Alan Ashworth
- Ping Wee
- Zhixiang Wang
- Andrew Tutt
- J. Blenis
- J. Reis-Filho
- Alexandr P. Kornev
Citations in the corpus
- Protein Kinases: Evolution of Dynamic Regulatory Proteins (2010, background): “might be sufficient for this final processing, whereas in other cases, such as RSK, five or more kinases are required [45].”
- ERK/MAPK signalling pathway and tumorigenesis (2020, background): “ERK, a type of serine/threonine protein kinase, is a signal transduction protein that transmits mitogen signals (32).”
- Bidirectional Transport of Amino Acids Regulates mTOR and Autophagy (2009, neutral): “consistent with the ability of RSK to directly phosphorylate S6 in a mTORC1-independent manner (Anjum and Blenis, 2008).”
- Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways (2017, background): “Post-translationally, ERK activates RSK, which activates c-FOS [209].”
- The Ras-ERK and PI3K-mTOR Pathways: Cross-talk and Compensation (2011, background): “The IEG products, such as c-Fos and c-Myc, induce late-response genes that promote cell survival, cell division, and cell motility [3, 4].”
- The nuts and bolts of AGC protein kinases (2010, background): “MAPKs dock to the C-terminus of RSK and MSK and phosphorylate and activate their CTK”
- ERK1/2 MAP kinases: structure, function, and regulation. (2012, background): “The 90 kDa ribosomal S6 kinase (RSK) family of proteins is a group of protein-serine/threonine kinases that regulate cell growth, motility, proliferation, and survival [91].”
- FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer (2010, positive): “Ribosomal S6 kinase (RSK), a down stream effector of MAPK signalling(28-30), was also phosphorylated in response to FGF2 only in amplified cell lines (Supplementary Figure 4).”